Answers are grounded in this paper and cite their sources.
This research demonstrates aloe-emodin's inhibition of the PI3K/Akt/mTOR pathway in nasopharyngeal carcinoma cells, highlighting its potential therapeutic effects.
Long non-coding RNAs (lncRNAs) are dysregulated in nasopharyngeal carcinoma (NPC), yet their interplay with pharmacological agents like aloe-emodin (AE) remains unclear. This study explores AE's anti-NPC mechanisms via lncRNA D63785 and the PI3K/Akt/mTOR pathway. NPC cells (CNE1, C666-1) were treated with AE, followed by qRT-PCR and Western blotting to assess lncRNA D63785 and PI3K/Akt/mTOR pathway proteins. siRNA-mediated lncRNA D63785 knockdown combined with functional assays (CCK-8, EdU, colony/wound-healing) evaluated AE's effects on proliferation, migration, and pathway activity. In vivo validation used nude mouse xenografts. LncRNA D63785 was overexpressed in NPC cells (p < 0.01). AE suppressed lncRNA D63785 expression, concurrently reducing PI3K/Akt/mTOR phosphorylation (p < 0.05). siRNA knockdown partially reversed AE's inhibition of NPC cell viability, proliferation, and migration. In vivo, AE attenuated tumor growth (p < 0.05), correlating with lncRNA D63785 downregulation and PI3K/Akt/mTOR dephosphorylation. AE exerts anti-NPC effects by targeting the lncRNA D63785-PI3K/Akt/mTOR axis, offering a novel therapeutic strategy. These findings bridge AE's pharmacological activity with lncRNA regulatory networks in NPC pathogenesis.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: